PL2663336T3 - Sposoby i odczynniki do skutecznego i ukierunkowanego dostarczania cząstek terapeutycznych do komórek cxcr4 - Google Patents

Sposoby i odczynniki do skutecznego i ukierunkowanego dostarczania cząstek terapeutycznych do komórek cxcr4

Info

Publication number
PL2663336T3
PL2663336T3 PL12704711T PL12704711T PL2663336T3 PL 2663336 T3 PL2663336 T3 PL 2663336T3 PL 12704711 T PL12704711 T PL 12704711T PL 12704711 T PL12704711 T PL 12704711T PL 2663336 T3 PL2663336 T3 PL 2663336T3
Authority
PL
Poland
Prior art keywords
reagents
efficient
methods
targeted delivery
therapeutic molecules
Prior art date
Application number
PL12704711T
Other languages
English (en)
Inventor
Corrales Antonio Villaverde
GÓMEZ Esther VÁZQUEZ
Navarro María Virtudes Céspedes
Rigat Isolda Casanova
Miralles Neus Ferrer
Bafalluy Ramon Mangues
Elorza Ugutz Unzueta
Original Assignee
UNIV AUTòNOMA DE BARCELONA
Fundacio Inst De Recerca De Lhospital De La Santa Creu I Sant Pau
Centro De Investig Biomedica En Red
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UNIV AUTòNOMA DE BARCELONA, Fundacio Inst De Recerca De Lhospital De La Santa Creu I Sant Pau, Centro De Investig Biomedica En Red filed Critical UNIV AUTòNOMA DE BARCELONA
Publication of PL2663336T3 publication Critical patent/PL2663336T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL12704711T 2011-01-13 2012-01-13 Sposoby i odczynniki do skutecznego i ukierunkowanego dostarczania cząstek terapeutycznych do komórek cxcr4 PL2663336T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11382005A EP2476441A1 (en) 2011-01-13 2011-01-13 Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells
EP12704711.6A EP2663336B1 (en) 2011-01-13 2012-01-13 Methods and reagents for efficient and targeted delivery of therapeutic molecules to cxcr4 cells
PCT/EP2012/050513 WO2012095527A1 (en) 2011-01-13 2012-01-13 Methods and reagents for efficient and targeted delivery of therapeutic molecules to cxcr4 cells

Publications (1)

Publication Number Publication Date
PL2663336T3 true PL2663336T3 (pl) 2018-01-31

Family

ID=43983350

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12704711T PL2663336T3 (pl) 2011-01-13 2012-01-13 Sposoby i odczynniki do skutecznego i ukierunkowanego dostarczania cząstek terapeutycznych do komórek cxcr4

Country Status (11)

Country Link
US (4) US9580468B2 (pl)
EP (2) EP2476441A1 (pl)
JP (1) JP2014508515A (pl)
CN (1) CN103501818A (pl)
AU (1) AU2012206533B2 (pl)
DK (1) DK2663336T3 (pl)
ES (1) ES2646390T3 (pl)
IL (1) IL227442B (pl)
PL (1) PL2663336T3 (pl)
PT (1) PT2663336T (pl)
WO (1) WO2012095527A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106414483A (zh) 2014-01-27 2017-02-15 分子模板公司 用于哺乳动物中的去免疫化志贺毒素a亚基效应子多肽
CN103789333B (zh) * 2014-03-05 2016-02-24 湖北肽洋红生物工程有限公司 一种口服重组融合蛋白tat-map30及制备方法和应用
US10815469B2 (en) * 2014-06-11 2020-10-27 Molecular Templates, Inc. Cell-targeting molecules comprising protease-cleavage resistant, Shiga toxin A subunit effector polypeptides and carboxy-terminal moieties
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
CN105859841B (zh) * 2016-03-04 2019-09-20 中山大学 一种双靶向嵌合肽及其在制备抗肿瘤转移药物中的应用
CN106086075B (zh) * 2016-06-23 2019-08-06 福建医科大学 CXCR4RNAi慢病毒载体的构建方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
MX2019009821A (es) * 2017-02-21 2019-12-02 Kura Oncology Inc Metodos para tratar cancer con inhibidores de farnesiltransferasa.
US20200239529A1 (en) * 2017-05-05 2020-07-30 Universitat Autònoma De Barcelona Nanostructured proteins and uses thereof
JP7289029B2 (ja) 2017-07-10 2023-06-09 エスアールアイ インターナショナル 分子誘導システムペプチド及びその使用
CN111417646B (zh) * 2017-07-10 2024-04-19 斯坦福国际研究院 用于治疗癌症的肽皂草素缀合物
EP3427756A1 (en) * 2017-07-14 2019-01-16 Universidad Autónoma De Barcelona (UAB) Therapeutic nanoconjugates and uses thereof
CN107325187B (zh) * 2017-07-19 2021-11-09 黄子为 一种具有cxcr4蛋白激动活性的多肽及其应用和药物组合物
US10639379B2 (en) * 2017-09-05 2020-05-05 Mainline Biosciences Llc High affinity CXCR4 selective binding conjugate and method for using the same
KR20210095859A (ko) * 2018-09-25 2021-08-03 에모리 유니버시티 세포 인식 및 통합을 위한 핵산
WO2020177717A1 (zh) * 2019-03-04 2020-09-10 上海一宸医药科技有限公司 新型双特异性结合分子及其药物偶联物
CA3134836A1 (en) * 2019-04-01 2020-10-08 Cytodyn Inc. Anti-ccr5 agents and methods of treatment that block cancer metastasis or enhance cell death induced by dna damaging chemotherapy
EP3722255A1 (en) * 2019-04-11 2020-10-14 Universitat Autònoma De Barcelona Protein nano- or microparticles as artificial inclusion bodies
BR112021020304A2 (pt) * 2019-04-11 2021-12-28 Consorcio Centro De Investig Biomedica En Red M P Ciber Nano ou micropartícula de proteína, nano ou micropartícula de proteína-lipídio, método para a síntese de uma nano ou micropartícula de proteína, método para a síntese de uma nano ou micropartícula de proteína-lipídio, nano ou micropartícula de proteína para uso e composição farmacêutica
EP3842452A1 (en) * 2019-12-26 2021-06-30 Universitat Autònoma de Barcelona Scaffold proteins and therapeutic nanoconjugates based on nidogen
WO2023133422A1 (en) * 2022-01-04 2023-07-13 The Broad Institute, Inc. Compositions and methods for delivering cargo to a target cell

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US5082927A (en) 1986-09-24 1992-01-21 The United States Of America As Represented By The Department Of Health And Human Services Selectively cytotoxic IL-4-PE40 fusion protein
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5087617A (en) 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
NO921715L (no) * 1991-05-02 1992-11-03 Seikagaku Kogyo Co Ltd Nye polypeptider med affinitet for lipopolysakkarider og anvendelser derav
US5622958A (en) 1994-12-01 1997-04-22 Sloan-Kettering Institute For Cancer Research Enediyne quinone imines and methods of preparation and use thereof
WO1999036518A1 (en) 1998-01-15 1999-07-22 Btg International Limited Ribozymal nucleic acids cleaving ccr5 or cxcr4
US6429308B1 (en) 1998-11-24 2002-08-06 Hisamitsu Pharmaceutical Co., Inc. HIV infection inhibitors
CA2414650A1 (en) * 2000-06-30 2002-01-10 Board Of Regents, The University Of Texas System Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
US20050124569A1 (en) 2001-05-18 2005-06-09 Sirna Therapeutics, Inc. RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
US20040132642A1 (en) * 2002-11-12 2004-07-08 Government Of The U.S.A., Represented By The Secretary, Dept. Of Health & Human Services Methods of inhibiting metastasis or growth of a tumor cell
US20050113324A1 (en) * 2003-01-15 2005-05-26 Bondarev Igor E. Modulation of line-1 reverse transcriptase
WO2004087068A2 (en) 2003-03-27 2004-10-14 Emory University Cxcr4 antagonists and methods of their use
US20090098049A1 (en) 2004-09-07 2009-04-16 The Regents Of The University Of California Targeting transducible molecules to specific cell types
AU2006339519A1 (en) 2005-12-16 2007-09-13 The Uab Research Foundation Compositions and methods related to controlled gene expression using viral vectors
WO2007115376A1 (en) 2006-04-11 2007-10-18 The University Of Western Australia Anti-angiogenic agents and methods of their use
US20090105182A1 (en) 2006-06-02 2009-04-23 Alcon Research, Ltd. RNAi-MEDIATED INHIBITION OF STROMAL CELL-DERIVED FACTOR 1-RELATED TARGETS FOR TREATMENT OF NEOVASCULARIZATION-RELATED CONDITIONS
WO2008008852A2 (en) 2006-07-11 2008-01-17 Emory University Cxcr4 antagonists including heteroatoms for the treatment of medical disorders
WO2008124483A1 (en) 2007-04-04 2008-10-16 Specigen, Inc. Protein cage immunotherapeutics
WO2009033792A2 (en) 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Gamma 1 msh alone or in combination with pentagastrin as a therapeutic agent
US7908940B2 (en) 2008-03-24 2011-03-22 Shimano Inc. Bar end electric shifter
TWI431014B (zh) * 2008-10-29 2014-03-21 Academia Sinica 腫瘤標靶胜肽及其於檢測及治療癌症之用途
EP2370055A2 (en) * 2008-11-30 2011-10-05 University Of The Witwatersrand, Johannesburg Polymeric pharmaceutical dosage form in sustained release

Also Published As

Publication number Publication date
DK2663336T3 (da) 2017-11-27
EP2663336A1 (en) 2013-11-20
AU2012206533A1 (en) 2013-08-01
US10813975B2 (en) 2020-10-27
IL227442B (en) 2018-05-31
EP2476441A1 (en) 2012-07-18
US20190183968A1 (en) 2019-06-20
US20210008154A1 (en) 2021-01-14
US11590198B2 (en) 2023-02-28
US20140094404A1 (en) 2014-04-03
PT2663336T (pt) 2017-11-15
EP2663336B1 (en) 2017-08-09
CN103501818A (zh) 2014-01-08
WO2012095527A1 (en) 2012-07-19
AU2012206533B2 (en) 2017-08-31
US20170209590A1 (en) 2017-07-27
IL227442A0 (en) 2013-09-30
ES2646390T3 (es) 2017-12-13
JP2014508515A (ja) 2014-04-10
US10265371B2 (en) 2019-04-23
US9580468B2 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
IL227442B (en) Methods and reagents for targeted and efficient delivery of therapeutic molecules to cxcr4 cells
IL288241A (en) Improved cell culture methods for stress cell therapy
IL282219B (en) Humanized antibodies to pcsk9 for use in the treatment of certain groups of people
IL271005A (en) Improved cell culture methods for stress cell therapy
HK1249548A1 (zh) 用於無脈絡膜的基因療法的aav載體
HK1197184A1 (en) Selective delivery molecules and methods of use
LT2560687T (lt) Kompozicijos ir būdai, skirti selektyviam oligonukleotido molekulių pristatymui specifiniams neuronų tipams
HK1202796A1 (en) Delivery system for specifically targeting cancer cells and method of use thereof
EP2836501A4 (en) RNA APTAMERS FOR THERAPEUTIC AND DIAGNOSTIC ADMINISTRATION ON PANCREAS CRAB CELLS
BR112013014076A2 (pt) métodos de direcionamento metabólico de células de câncer usando quimio- e imunotherapia para tratamento de câncer
IL228953A0 (en) A method to create materials with a super-saturation of gas, their introduction through the skin and their uses
EP2753359A4 (en) SERPINF2 BINDEMOLEKÜLE AND METHOD FOR THEIR USE
SG11201401038VA (en) Isolating and therapeutic use of perivascular medicinal cells
EP2751137A4 (en) MOLECULAR GENETIC APPROACH FOR THE TREATMENT AND DIAGNOSIS OF ALCOHOL DEPENDENCE AND PHARMACODEPPENDANCE
EP2751126A4 (en) USE OF HDL MOLECULES FOR THE TREATMENT AND PREVENTION OF PROINFLAMMATORY SUFFERING
PT3395836T (pt) Anticorpos humanos para pcsk9 para uso em métodos de tratar grupos específicos de sujeitos